<?xml version="1.0" encoding="UTF-8"?>
<p>Ibrutinib treatment requires few routine treatment visits and lab assessments.
 <sup>
  <xref rid="R54" ref-type="bibr">54</xref>
 </sup> It is associated with a low risk of neutropenia, and the immune reconstitution of T-cells, which in turns decreases the infection rate after the first 6 months of therapy.
 <sup>
  <xref rid="R54" ref-type="bibr">54</xref>,
  <xref rid="R80" ref-type="bibr">80</xref>,
  <xref rid="R84" ref-type="bibr">84</xref>,
  <xref rid="R85" ref-type="bibr">85</xref>
 </sup> BTK inhibitors are also undergoing investigation (NCT04346199) as an anti-inflammatory therapy in COVID-19, based on a few reports from uncontrolled clinical cases.
 <sup>
  <xref rid="R86" ref-type="bibr">86</xref>,
  <xref rid="R87" ref-type="bibr">87</xref>
 </sup> The disadvantage of ibrutinib treatment during SARS-CoV-2 outbreak is the continuous schedule not allowing treatment free intervals. However, if ibrutinib is discontinued because of an adverse event while CLL is in remission, the disease may continue being under control for a prolonged period of time before an alternative therapy is required.
 <sup>
  <xref rid="R46" ref-type="bibr">46</xref>,
  <xref rid="R50" ref-type="bibr">50</xref>,
  <xref rid="R88" ref-type="bibr">88</xref>â€“
  <xref rid="R90" ref-type="bibr">90</xref>
 </sup>
</p>
